Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient (PHASR)
This study is currently recruiting participants.
Verified December 2011 by Catholic Health East
Sponsor:
Catholic Health East
Information provided by (Responsible Party):
Derek Isenberg, Catholic Health East
ClinicalTrials.gov Identifier:
NCT01501123
First received: December 27, 2011
Last updated: December 28, 2011
Last verified: December 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
PREHOSPITAL AGITATION AND SEDATION TRIAL (PHAST)
- The goal of the PHAST is to demine whether haloperidol is superior to midazolam for the sedation of agitated patients in the prehospital environment
The primary outcome is the time to a Richmond Agitation and Sedation Scale (RASS) ≤1
o The RASS is a well validated standardized score to measure a patient's agitation
The secondary outcomes are
- Time until RASS returns to 0 or 1 if RASS <0
- Need for additional sedation
- Adverse effects (need for intubation, arrhythmia)
- Mercy EMS will be the only EMS agency in the Commonwealth of Pennsylvania carrying haloperidol
- Identification of potential study patients will be per state protocols
- Exclusion Criteria for the study
- Age <18
- Pregnant
- Allergic to study medication
- Transport to hospital other than Mercy Fitzgerald Hospital
- Unable to reach medical command prior to giving medication
- When a paramedic identifies a possible study candidate, the paramedic will consult medical command to see if the patient is appropriate for the study
- If the medical command agrees the patient is appropriate for the study, patients will be randomized to
- Odd days: Haloperidol 5mg IM (age <65) or haloperidol 2.5 mg IM (age ≥65)
- Even days: Midazolam 0.05 mg IM to maximum of 5mg IM (age <65) or maximum of 2.5mg (age ≥65)
- The RASS will be documented by the prehospital providers every 5 minutes until arrival at the hospital
- Once the patient arrives at the ED, the RASS will be documented in PICIS® by the emergency department nurse at the time of triage and at a minimum of hourly until the RASS =0 or 1 for 2 consecutive hours
- Questions may be directed to Dr. Isenberg at disenberg@mercyhealth.org or at (267) 205-6453
Richmond Agitation Sedation Scale
RASS RASS Description
- 4 Combative, violent, danger to staff
- 3 Pulls or removes tube(s) or catheters; aggressive
- 2 Frequent non-purposeful movement
1 Anxious, apprehensive, but not aggressive 0 Alert and calm
- 1 Awakens to voice (eye opening/contact) >10 sec
- 2 Light sedation, briefly awakens to voice (eye opening/contact) <10 sec
- 3 Moderate sedation, movement or eye opening. No eye contact
- 4 Deep sedation, no response to voice, but movement or eye opening to physical stimulation
- 5 Unarousable, no response to voice or physical stimulation
| Condition | Intervention |
|---|---|
|
Agitation |
Drug: Haloperidol Drug: Midazolam |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Re-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient |
Resource links provided by NLM:
Further study details as provided by Catholic Health East:
Primary Outcome Measures:
- Time to sedation [ Time Frame: 10 minutes ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 162 |
| Study Start Date: | November 2011 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Haloperidol
IM Haloperidol
|
Drug: Haloperidol
5mg IM
|
| Active Comparator: Midazolam | Drug: Midazolam |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Exclusion Criteria:
- Age <18
- Pregnant
- Allergic to study medication
- Transport to hospital other than Mercy Fitzgerald Hospital
- Unable to reach medical command prior to giving medication
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01501123
Contacts
| Contact: Derek Isenberg, MD | 9043738034 |
Locations
| United States, Pennsylvania | |
| Mercy Catholic Medical Center | Recruiting |
| Darby, Pennsylvania, United States, 19023 | |
Sponsors and Collaborators
Catholic Health East
Investigators
| Principal Investigator: | Derek Isenberg, MD | Mercy Catholic Medical Center |
More Information
No publications provided
| Responsible Party: | Derek Isenberg, MD, Catholic Health East |
| ClinicalTrials.gov Identifier: | NCT01501123 History of Changes |
| Other Study ID Numbers: | MCMC 2010-24 |
| Study First Received: | December 27, 2011 |
| Last Updated: | December 28, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Catholic Health East:
|
Time to sedation of agitated patients |
Additional relevant MeSH terms:
|
Psychomotor Agitation Dyskinesias Neurologic Manifestations Nervous System Diseases Psychomotor Disorders Neurobehavioral Manifestations Signs and Symptoms Midazolam Haloperidol Haloperidol decanoate Adjuvants, Anesthesia Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Anti-Anxiety Agents |
Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Psychotropic Drugs Hypnotics and Sedatives Anesthetics, Intravenous Anesthetics, General Anesthetics GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Antiemetics Autonomic Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on May 22, 2013